{"id":55084,"date":"2025-07-30T08:38:21","date_gmt":"2025-07-30T08:38:21","guid":{"rendered":"https:\/\/ibima.eu\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\/"},"modified":"2025-07-30T08:38:21","modified_gmt":"2025-07-30T08:38:21","slug":"a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus","status":"publish","type":"post","link":"https:\/\/ibima.eu\/es\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\/","title":{"rendered":"A randomized, controlled, open-label, phase III trial on Adjuvant Dynamic marker \u2013 Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+\/HER2- early breast cancer (ADAPTlate)"},"content":{"rendered":"<p>TAMARA D\u00cdAZ REDONDO &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; WSG WESTDEUTSCHE STUDIENGRUPPE GMBH<\/p>\n","protected":false},"excerpt":{"rendered":"<p>TAMARA D\u00cdAZ REDONDO &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; WSG WESTDEUTSCHE STUDIENGRUPPE GMBH<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2683],"tags":[],"class_list":["post-55084","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-b-22"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>A randomized, controlled, open-label, phase III trial on Adjuvant Dynamic marker \u2013 Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+\/HER2- early breast cancer (ADAPTlate) - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/es\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A randomized, controlled, open-label, phase III trial on Adjuvant Dynamic marker \u2013 Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+\/HER2- early breast cancer (ADAPTlate) - Ibima\" \/>\n<meta property=\"og:description\" content=\"TAMARA D\u00cdAZ REDONDO &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; WSG WESTDEUTSCHE STUDIENGRUPPE GMBH\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/es\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-30T08:38:21+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"A randomized, controlled, open-label, phase III trial on Adjuvant Dynamic marker \u2013 Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+\\\/HER2- early breast cancer (ADAPTlate)\",\"datePublished\":\"2025-07-30T08:38:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\\\/\"},\"wordCount\":58,\"commentCount\":0,\"articleSection\":[\"Ensayos Cl\u00ednicos\",\"Ensayos Cl\u00ednicos - B-22\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\\\/\",\"name\":\"A randomized, controlled, open-label, phase III trial on Adjuvant Dynamic marker \u2013 Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+\\\/HER2- early breast cancer (ADAPTlate) - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-07-30T08:38:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A randomized, controlled, open-label, phase III trial on Adjuvant Dynamic marker \u2013 Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+\\\/HER2- early breast cancer (ADAPTlate)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A randomized, controlled, open-label, phase III trial on Adjuvant Dynamic marker \u2013 Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+\/HER2- early breast cancer (ADAPTlate) - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/es\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\/","og_locale":"es_ES","og_type":"article","og_title":"A randomized, controlled, open-label, phase III trial on Adjuvant Dynamic marker \u2013 Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+\/HER2- early breast cancer (ADAPTlate) - Ibima","og_description":"TAMARA D\u00cdAZ REDONDO &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; WSG WESTDEUTSCHE STUDIENGRUPPE GMBH","og_url":"https:\/\/ibima.eu\/es\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\/","og_site_name":"Ibima","article_published_time":"2025-07-30T08:38:21+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"A randomized, controlled, open-label, phase III trial on Adjuvant Dynamic marker \u2013 Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+\/HER2- early breast cancer (ADAPTlate)","datePublished":"2025-07-30T08:38:21+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\/"},"wordCount":58,"commentCount":0,"articleSection":["Ensayos Cl\u00ednicos","Ensayos Cl\u00ednicos - B-22"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\/","url":"https:\/\/ibima.eu\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\/","name":"A randomized, controlled, open-label, phase III trial on Adjuvant Dynamic marker \u2013 Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+\/HER2- early breast cancer (ADAPTlate) - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-07-30T08:38:21+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/a-randomized-controlled-open-label-phase-iii-trial-on-adjuvant-dynamic-marker-adjusted-personalized-therapy-comparing-abemaciclib-combined-with-standard-adjuvant-endocrine-therapy-versus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"A randomized, controlled, open-label, phase III trial on Adjuvant Dynamic marker \u2013 Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+\/HER2- early breast cancer (ADAPTlate)"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/es\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/55084","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/comments?post=55084"}],"version-history":[{"count":0,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/55084\/revisions"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/media?parent=55084"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/categories?post=55084"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/tags?post=55084"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}